What is documented
Published clinical literature, official records where available, and clearly attributed accounts are distinguished from secondary repetition.
Documented incidents · cautious attribution
Case Catalogue
Ibogaine Deaths: What The Record Documents.
A structured reading of reported fatal incidents and case series: what is described, what is absent, and where the available record does not support certainty.
Scope of the catalogue
A record is not a verdict.
This catalogue is organized around individual documented fatal incidents and representative case series associated with ibogaine exposure. Its purpose is to preserve distinctions among reported timing, substances present, treatment setting, clinical findings, autopsy information, and stated conclusions.
It is intended to be used alongside the broader framework for reading ibogaine-associated deaths, not as a count of proven causes. For background on how this independent resource approaches uncertainty and source limits, see the statement of purpose and methods.
Cases are included when a primary or near-primary source identifies ibogaine or an ibogaine-containing preparation in the circumstances of death. The catalogue does not convert an association into a causal finding when the source itself does not do so.
Inclusion method
Three fields kept separate in every annotation.
What surrounded the event
Setting, co-exposures, monitoring, reported medical history, and treatment sequence are retained because they can materially change interpretation.
What cannot be resolved
Each note identifies whether a mechanism was observed, suspected, contested, or not established in the source record.
Selected annotations
How entries are read.
Entries below describe recurring documentation patterns rather than claiming a complete global ledger. They are standardized by year or publication period, country or setting when reported, substances, key findings, and the degree of attribution uncertainty.
Case series
Forensic literature
Forensic literature
Postmortem cases with ibogaine identified
Published forensic accounts have described deaths in which ibogaine was identified after death, sometimes alongside opioids, stimulants, alcohol, or other medicines. The presence of multiple substances, variable postmortem testing, and incomplete clinical histories limits the inference available from toxicology alone.
Annotation: setting is often not fully described; substances may include co-exposures; findings may include postmortem toxicology and autopsy observations; attribution remains uncertain unless a source directly establishes a mechanism.
Treatment setting
Reported incidents
Reported incidents
Events reported during or after treatment-oriented use
Some accounts describe use in a treatment context, including settings that characterize themselves as supervised. That label alone does not reveal pre-treatment screening, continuous monitoring, emergency readiness, dose, co-medications, or what occurred after dosing. Questions about these conditions matter in any discussion of supervised ibogaine practices.
Annotation: setting may be described as clinic-like or residential; reported findings may include collapse, rhythm disturbance, or delayed deterioration; the record may not establish whether all relevant risk factors were known beforehand.
Home / informal
Variable records
Variable records
Unobserved intervals and incomplete treatment histories
In home or informal settings, the interval between ingestion, symptoms, discovery, and emergency care may be unclear. Product identity can also be uncertain, particularly where a preparation is discussed as an ibogaine supplement rather than a documented pharmaceutical product.
Annotation: setting may be home or informal; substances may be self-reported or inferred; key findings can be absent or limited to emergency and postmortem records; uncertainty is commonly high.
Clinical vulnerability
Mechanism considered
Mechanism considered
Arrhythmia, electrolyte findings, and interacting exposures
Where records mention cardiac rhythm abnormalities or electrolyte disturbance, those details are kept distinct from a conclusion that ibogaine alone caused death. The U.S. Food and Drug Administration describes QT-related abnormal heart rhythm risk as a medication-safety concern in other drug contexts; that general principle helps explain why ECG findings, electrolyte results, and co-medications are important details to document.
Annotation: source may report arrhythmia, electrolyte abnormality, or a relevant cardiac history; the contribution of each factor may remain indeterminate without contemporaneous records and complete toxicology.
Known limitations
Absence of a record is not absence of an event.
Fatal incidents may be underreported, reported without enough detail to classify, or described in sources that cannot be independently checked. Conversely, highly visible cases can be repeated across publications and online accounts in ways that make a single event appear to be several.
Public health surveillance depends on consistent definitions and data collection; the CDC’s overview of public health surveillance underscores why variable reporting systems cannot be treated as a seamless denominator. The catalogue therefore favors explicit uncertainty over apparent precision.
“A careful case record preserves the boundary between what was observed and what was inferred.”
Reading across cases
Recurring patterns, without a causal shortcut.
Across documented accounts, recurring considerations include uncertain product composition, simultaneous or recent substance use, variable medical screening, cardiac vulnerability, electrolyte status, and gaps in observation or transfer to emergency care. These are patterns in the record, not proof that any one factor explains every death.
Outliers matter too. A case with detailed hospital data, autopsy findings, and toxicology may support a narrower discussion than a report with only a reported exposure and limited chronology. The general reference overview of ibogaine reflects the compound’s complex medical and legal context, but it cannot substitute for incident-level evidence.
- Co-exposures and pre-existing conditions can complicate attribution.
- Descriptions of treatment setting do not establish the quality or continuity of monitoring.
- Postmortem findings can be informative while still leaving the sequence of events unresolved.
- Representative case series illuminate mechanisms considered by authors, not a complete incidence rate.
Interpretation notes
Questions the catalogue is designed to keep open.
Does a documented death prove ibogaine caused it?
No. A documented temporal association is not, by itself, proof of direct causation. Interpretation depends on the available clinical, toxicological, forensic, and contextual record. This distinction is especially relevant where ibogaine is discussed in connection with PTSD treatment claims.
Why might records be incomplete?
Deaths may occur in settings with variable oversight; autopsies and toxicology differ by jurisdiction; and public accounts may omit material details. Similar gaps can affect discussions of ibogaine treatment for veterans, where a named population does not make the underlying evidence uniform.
What does uncertainty mean in an annotation?
It records what source materials do and do not establish. The same caution applies when comparing European ibogaine treatment settings: location or self-description does not resolve the medical or forensic details of an individual incident.
Why include relapse-related context?
Some records include recent opioid use, withdrawal, or return to use among several possible contextual factors. That context should not be flattened into a single explanation; discussions of ibogaine and relapse require the same distinction between a reported circumstance and a demonstrated mechanism.
Continue carefully
Use the catalogue as a starting point, not a conclusion.
For a structured view of factors that can complicate interpretation across cases, consult the site’s risk-focused material.